Novel Techniques, Biomarkers and Molecular Targets to Address Cardiometabolic Diseases DOI Open Access

Valerio Fiore,

Federica Cappelli,

Lavinia Del Punta

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(10), P. 2883 - 2883

Published: May 14, 2024

Cardiometabolic diseases (CMDs) are interrelated and multifactorial conditions, including arterial hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke. Due to the burden of cardiovascular morbidity mortality associated with CMDs' increasing prevalence, there is a critical need for novel diagnostic therapeutic strategies in their management. In clinical practice, innovative methods such as epicardial adipose tissue evaluation, ventricular-arterial coupling, exercise tolerance studies could help elucidate multifaceted mechanisms CMDs. Similarly, epigenetic changes involving noncoding RNAs, chromatin modulation, cellular senescence represent both biomarkers targets Despite promising data available, significant challenges remain translating basic research findings into highlighting further investigation complex pathophysiology underlying

Language: Английский

Integrative assessment of congestion in heart failure using ultrasound imaging DOI Creative Commons

Valerio Fiore,

Lavinia Del Punta,

Nicolò De Biase

et al.

Internal and Emergency Medicine, Journal Year: 2024, Volume and Issue: unknown

Published: Sept. 5, 2024

Language: Английский

Citations

5
Performance Analysis of Denoising Filters for Ultrasound Fetal Head Images DOI
Kauleshwar Prasad, Pawan Kumar Patnaik, Anupam Agrawal

et al.

SN Computer Science, Journal Year: 2025, Volume and Issue: 6(2)

Published: Jan. 23, 2025

Language: Английский

Citations

0
Plasma CA125 Levels as a Predictor of Major Adverse Cardiac Events in Acute Coronary Syndrome Patients: A Six-Month Follow-Up Study DOI Creative Commons

Nazlı Dilek Çolak,

Turgut Karabağ,

Onuralp Çalışkan

et al.

Research Square (Research Square), Journal Year: 2025, Volume and Issue: unknown

Published: March 17, 2025

Abstract Objectives: Carbohydrate antigen 125 (CA125) is associated with different heart conditions. The study aims to determine CA125 levels in patients ACS and the potential relationship between major adverse cardiac events (MACE) a short-term following. Methods: This was prospective cross-sectional conducted cardiology clinic May August 2022. Plasma were measured only once on hospital admission. Patients followed for six months. presence of MACE (cardiac death, recurrent ACS, need revascularization, decompensated failure, hypertensive cardiogenic pulmonary edema) recorded. Results: A total 127 included study. mean left ventricular ejection fraction (LVEF) 50.5%. plasma median value 14.6 KU/L. It determined that there positive, significant hsTroponinT (r=0.315, p<0.001) proBNP (r=0.423, p<0.001), negative LVEF (r=-0.186, p=0.037) value. Conclusions: found correlated biomarkers (proBNP hs-cTnT). Another interesting result correlation predictive LVEF. Elevated might be used identify higher risk at 6

Language: Английский

Citations

0
Circulating Biomarkers in Pulmonary Arterial Hypertension: An Update DOI Creative Commons
Michele Correale, Lucia Tricarico,

Ester Maria Lucia Bevere

et al.

Biomolecules, Journal Year: 2024, Volume and Issue: 14(5), P. 552 - 552

Published: May 3, 2024

Pulmonary arterial hypertension (PAH) is a rare subtype of group 1 pulmonary (PH) diseases, characterized by high artery pressure leading to right ventricular dysfunction and potential life-threatening consequences. PAH involves complex mechanisms: vasoconstriction, vascular remodeling, endothelial dysfunction, inflammation, oxidative stress, fibrosis, RV cellular hypoxia, metabolic imbalance, thrombosis. These mechanisms are mediated several pathways, involving molecules like nitric oxide prostacyclin. diagnosis requires clinical evaluation heart catheterization, confirming value mPAP ≥ 20 mmHg at rest often elevated resistance (PVR). Even if an early accurate crucial, still lacks effective biomarkers assist in its prognosis. Biomarkers could contribute arousing suspicion serve for prognosis prediction, risk stratification, dynamic monitoring patients with PAH. The aim the present review report main novelties on new possible diagnosis, prognosis, treatment

Language: Английский

Citations

3
Fibrosis-specific biomarkers and interstitial fibrosis in hypertrophic cardiomyopathy DOI Open Access
Michele Correale, Francesco Santoro,

Damiamo Magrì

et al.

Kardiologia Polska, Journal Year: 2023, Volume and Issue: 81(7-8), P. 671 - 672

Published: Aug. 26, 2023

Language: Английский

Citations

4
Use of the biomarker score in determining the risk of heart failure in diabetics in Goma, North kivu in the Democractic Republic of the Congo DOI Creative Commons
Ferdinand Ng’ekieb Mukoso, Aliocha Natuhoyila Nkodila,

Hippolyte Nani tuma Situakibanza

et al.

International Journal of Cardiology Cardiovascular Risk and Prevention, Journal Year: 2024, Volume and Issue: 21, P. 200263 - 200263

Published: March 30, 2024

The use of biomarkers, such as N-terminal pro-brain natriuretic peptide (NTpBNP), high-sensitivity C-reactive protein (hs-CRP) and troponin (hs-TnI) is an alternative approach to detect the risk heart failure (HF), but data on this are fragmentary in sub-Saharan Africa. objective study determine correlation between score biomarkers population asymptomatic diabetics city GOMA.

Language: Английский

Citations

0
Novel Techniques, Biomarkers and Molecular Targets to Address Cardiometabolic Diseases DOI Open Access

Valerio Fiore,

Federica Cappelli,

Lavinia Del Punta

et al.

Journal of Clinical Medicine, Journal Year: 2024, Volume and Issue: 13(10), P. 2883 - 2883

Published: May 14, 2024

Cardiometabolic diseases (CMDs) are interrelated and multifactorial conditions, including arterial hypertension, type 2 diabetes, heart failure, coronary artery disease, stroke. Due to the burden of cardiovascular morbidity mortality associated with CMDs' increasing prevalence, there is a critical need for novel diagnostic therapeutic strategies in their management. In clinical practice, innovative methods such as epicardial adipose tissue evaluation, ventricular-arterial coupling, exercise tolerance studies could help elucidate multifaceted mechanisms CMDs. Similarly, epigenetic changes involving noncoding RNAs, chromatin modulation, cellular senescence represent both biomarkers targets Despite promising data available, significant challenges remain translating basic research findings into highlighting further investigation complex pathophysiology underlying

Language: Английский

Citations

0